News | January 16, 2013

Navidea Completes Clinical Trial for Radiopharmaceutical Agent to Image Alzheimer’s Disease

Company also obtains rights to two additional beta-amyloid imaging agents from AstraZeneca

clinical trial, Alzheimer's Disease

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral ?-amyloid in diagnosing Alzheimer’s disease (AD). The study was designed and conducted by Navidea’s partner, AstraZeneca, to assess the effects of various mass amounts of AZD4694 (NAV4694) on safety and the efficacy of positron emission tomography (PET) scanning in subjects with AD and in healthy volunteers (HVs). Evaluations were completed on the effects of two mass doses of the radioligand on binding parameters and overall image quality. These endpoints are typical and important requirements of drug registration dossiers filed with regulatory authorities for approval of diagnostic agents.

The completed trial was an open-label, non-randomized, multi-center, PET study in a total of 16 individuals (eight with mild to moderate AD and eight elderly HVs) each imaged on two PET systems at Karolinska Institutet sites in Stockholm, Sweden. The study included elderly HVs to demonstrate that no unexpected tracer mass effects of AZD4694 (NAV4694) in subjects with low or no cerebral ?-amyloid occur; to compare imaging parameters from healthy, non-AD subjects with those from subjects with AD; and to extend the safety database.

“We are very pleased to have completed this study addressing some of the fundamental requirements of diagnostic imaging agents seeking approval. We continue to make exciting progress with NAV4694, which has demonstrated important performance characteristics that we believe position it as a true ‘best-in-class’ second generation agent to aid in the diagnosis of Alzheimer’s disease,” said Cornelia Reininger, M.D., Ph.D., Navidea’s chief medical officer. “As previously reported in other Phase 2 studies, NAV4694 exhibits the strengths of 11C PIB, the benchmark amyloid imaging agent, but, as the agent is radio-labeled with 18F, has distribution characteristics that make it more practical to use. The data from these studies suggest that NAV4694 shows favorable sensitivity, specificity, rapid brain uptake yet decreased white-matter uptake which affords improved image clarity.”

Reininger added, “We remain very enthusiastic about the potential of NAV4694 to advance clinical capabilities in diagnostic and therapeutic development for Alzheimer’s disease. Results from this study are expected to be reported at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging. We look forward to initiation of the NAV4694 Phase 3 study in 2013.”

Navidea is also announcing that it has expanded its relationship with AstraZeneca and obtained rights to two additional ?-amyloid imaging agents. AZD2184 and AZD2995 expand Navidea’s intellectual property portfolio and are positioned for research use to further establish its leadership within the AD community in basic science research. AZD2184 and AZD2995 are 11C Positron Emission Tomography (PET) radioligand tracers discovered by AstraZeneca in collaboration with Karolinska Institutet in Stockholm. AstraZeneca entered the agreement to ensure that the compounds are available to KOLs and academic centers. Both parties believe that these agents may serve as useful laboratory tools to support additional investigation of Alzheimer’s disease. Financial terms related to the granting of the additional rights were not disclosed as they were not material.

About NAV4694

NAV4694 is a Fluorine-18 labeled precision radiopharmaceutical candidate for use in the imaging and evaluation of patients with signs or symptoms of cognitive impairment such as AD. It binds to ?-amyloid deposits in the brain that can then be imaged in PET scans. Amyloid plaque pathology is a required feature of AD diagnosis and the presence of amyloid pathology is a supportive feature for diagnosis of probable AD. Patients who are negative for amyloid pathology do not have AD. AZD4694 was licensed from AstraZeneca in December 2011.

For more information: www.navidea.com

 

Related Content

GE Healthcare and Theragnostics Partnering on PSMA PET/CT Imaging Agent
News | Prostate Cancer | October 16, 2019
GE Healthcare and Theragnostics have entered into a global commercial partnership for a new prostate-specific membrane...
Sponsored Content | Whitepapers | Clinical Trials | October 09, 2019
A 2019 N G PX REPORT
AI Accurately Detects Key Chest X-Ray Pneumonia Findings Within 10 Seconds
News | Artificial Intelligence | September 30, 2019
Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they...
AI Accurately Predicts Radiotherapy Side Effects for Head and Neck Cancer Patients
News | Artificial Intelligence | September 26, 2019
For the first time, a sophisticated computer model has been shown to accurately predict two of the most challenging...
Machine Learning Could Offer Faster, More Precise Cardiac MRI Scan Results
News | Magnetic Resonance Imaging (MRI) | September 25, 2019
Cardiac magnetic resonance imaging (MRI) analysis can be performed significantly faster with similar precision to...
Partial and Whole-Breast Radiotherapy After Lumpectomy Provide Equally Satisfying Cosmetic Results
News | Radiation Therapy | September 25, 2019
Whole breast radiation and partial breast radiation following a lumpectomy yield similar cosmetic outcomes for women...
Hippocampal Avoidance Using IMRT Now Recommended as Standard of Care for Brain Metastases
News | Radiation Therapy | September 24, 2019
Patients with brain metastases who received whole-brain radiotherapy that avoided memory-specific hippocampal neural...
High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | September 23, 2019
August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced th
Densitas Wins Major Procurement of Breast Density Software for DIMASOS Breast Screening Trial
News | Breast Density | September 20, 2019
Densitas Inc. announced it has won a procurement of its densitas densityai software for deployment in up to 24 breast...